molecules of the month


oral Akt inhibitor

Ph. I in advanced solid tumors

scaffold hopping and PK opt.

J. Med. Chem.

Nanjing Chia-Tai Tianqing Pharmaceutical Co., Ltd., Nanjing, CN

NTQ1062 Chemical Structure oral Akt inhibitor - Nanjing Chia-Tai Tianqing Pharmaceutical Co., Ltd., Nanjing, CN
3 mins read

Context. NTQ1062 (Nanjing Chia-Tai Tianqing; CTTQ) is an oral ATP-competitive Akt inhibitor being developed for cancer. Because the PI3K/Akt/mTOR pathway is one of the most commonly disrupted pathways in cancer, inhibitors targeting one or more of the three kinases have been hotly pursued. To date, five PI3K and three mTOR inhibitors have been approved, but favorable PK and safety data have hindered the approval of an Akt inhibitor for cancer. The compound, which is currently being evaluated in a Ph. I study in China (CTR20211999), joins a select list of Akt inhibitors being evaluated in various stages of clinical development. It remains to be seen whether the promising preclinical data will translate into decent efficacy and safety in patients. Editor…

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: